For patients with geographic atrophy, a severe form of age-related macular degeneration, the loss of central vision is permanent. The standard of care involves managing the condition's progression, not reversing its effects. Science Corporation, a neural engineering startup founded in 2021, is now offering a different path in Europe: a subretinal implant that, combined with a pair of specialized glasses, can restore functional central vision [Perplexity Sonar Pro Brief]. By September 2026, the company reported its PRIMA system was being commercially prescribed and implanted by doctors across 30 European countries [Morningstar / Business Wire, September 2026]. This milestone, backed by a reported $3.5 billion valuation, marks one of the first commercial deployments of a vision-restoring brain-computer interface for a defined patient population [TechCrunch, November 2026]. The company's ambition, however, extends far beyond the retina.
The PRIMA System's Clinical Wedge
The PRIMA device is a photovoltaic chip, roughly two millimeters wide, that is implanted beneath the retina. It works in concert with augmented-reality glasses equipped with a camera. The glasses capture the visual scene, process it, and project simplified images as near-infrared light pulses onto the implant. The chip then converts that light into electrical signals to stimulate surviving retinal neurons, which transmit the information to the brain [PMC, Retrieved 2026]. This approach is less invasive than cortical BCIs that interface directly with the brain, and it targets a specific anatomical breakdown in a well-understood disease.
Clinical results published in The New England Journal of Medicine demonstrated the implant restored functional central vision in patients blinded by geographic atrophy [Eyewire+, Retrieved 2026]. Science Corporation reported durable vision restoration at 36 months in its clinical program, a key data point for both regulators and clinicians considering the intervention [Business Wire, October 2026]. The CE mark, received in July 2026, was the regulatory green light that turned a clinical trial device into a prescribed medical product [Ophthalmology Times Europe, Retrieved 2026].
Funding a Frontier Medicine
Commercializing a surgically implanted medical device is a capital-intensive endeavor, requiring sustained funding for clinical trials, manufacturing, and physician training. Science Corporation has assembled a war chest to match. In March 2026, the company closed a $230 million Series C, bringing its total raised at the time to approximately $490 million [Business Wire, March 2026]. Just eight months later, it secured a $400 million Series D at a reported $3.5 billion valuation [TechCrunch, November 2026]. The investor list reflects a blend of venture capital and strategic healthcare interests, including Lightspeed Venture Partners, Khosla Ventures, Tenet Healthcare, and the Ackman Oxman Institute [Business Wire, March 2026] [TechCrunch, November 2026].
Series C (Mar 2026) | 230 | M USD
Series D (Nov 2026) | 400 | M USD
The Team Behind the Biohybrid Bet
The company is led by co-founder and CEO Max Hodak, a biomedical engineer whose career has been oriented around ambitious life science platforms. He was a co-founder and president of Neuralink and previously founded Transcriptic, an automated cloud lab for life sciences research [TechCrunch, December 2025] [Forbes, April 2016]. Co-founder Emma Zhou, the chief scientific officer, brings experience from both Neuralink and software engineering [Mastodon, Retrieved 2026]. To steer commercialization, the company appointed Darius Shahida as President in September 2026, tasking him with investor relations and global partnerships [Morningstar / Business Wire, September 2026]. The team has scaled from a handful of people to over 150 in three years, according to a company LinkedIn post [Antonia E. - Science | LinkedIn, Retrieved 2026].
A Platform Beyond Vision
While PRIMA is the lead commercial asset, Science Corporation's stated mission is to restore and extend life through neural engineering [Matt Helfgott - Science | LinkedIn, Retrieved 2026]. The company is developing a broader ecosystem it calls a "biohybrid" architecture, which integrates neurons with electronics [Science Corporation]. It also sells research tools, like its SciFi headstage, to academic and commercial labs working in neuroscience, pricing them from $1,024 [Science Corporation]. These products serve a dual purpose: generating revenue for the capital-intensive clinical work and building a foundational technology stack for future applications in cognition and mobility. The company has indicated trials for a brain sensor could begin in 2027 [The Next Web, Retrieved 2026].
The Road to the U.S. Clinic
The most immediate and significant hurdle is securing FDA approval to bring PRIMA to the large U.S. market. The company has stated the device is under FDA review, but that process is rigorous and its timeline uncertain [Perplexity Sonar Pro Brief]. Furthermore, commercial success depends on navigating complex reimbursement systems and training a sufficient cadre of ophthalmic surgeons in the implantation procedure. The company's ability to manage these operational challenges while advancing its longer-term research pipeline will test its execution.
For the target population,patients with geographic atrophy secondary to age-related macular degeneration,the standard of care today is largely about slowing degeneration, not restoring what is lost. Treatments may include intravitreal injections or dietary supplements aimed at preserving remaining vision, but they do not reverse central blindness [PMC, Retrieved 2026]. The arrival of a device like PRIMA represents a paradigm shift, from management to restoration. Its commercial launch in Europe provides the first real-world test of whether that shift can be delivered reliably, safely, and at a scale that matters to patients.
Sources
- [Perplexity Sonar Pro Brief] Science Corporation brief |
- [Morningstar / Business Wire, September 2026] Science Corporation Names Darius Shahida as President | https://www.morningstar.com/news/business-wire/20260917593792/science-corporation-names-darius-shahida-as-president
- [TechCrunch, November 2026] Science Corporation's brain tech is worth $3.5 billion after new funding | https://techcrunch.com/2026/11/17/science-corporations-brain-tech-is-worth-3-5-billion-after-new-funding/
- [PMC, Retrieved 2026] PRIMA system description |
- [Eyewire+, Retrieved 2026] The New England Journal of Medicine Reports Science Corp.'s PRIMA BCI Implant Restores Functional Central Vision | https://science.xyz/news/new-england-journal-of-medicine-prima/
- [Business Wire, October 2026] PRIMA BCI clinical trial showed durable vision restoration at 36 months | https://science.xyz/news/new-england-journal-of-medicine-prima/
- [Ophthalmology Times Europe, Retrieved 2026] PRIMA received a CE mark from DEKRA |
- [Business Wire, March 2026] Science Corporation Closes $230 Million Series C | https://www.businesswire.com/news/home/20260305896789/en/Science-Corporation-Closes-$230-Million-Series-C-to-Accelerate-Commercialization-of-Its-PRIMA-BCI-Retinal-Implant-the-World%E2%80%99s-Most-Advanced-Vision-Restoration-Technology
- [TechCrunch, December 2025] After Neuralink, Max Hodak is building something even wilder | https://techcrunch.com/2025/12/05/after-neuralink-max-hodak-is-building-something-stranger/
- [Forbes, April 2016] Max Hodak was co-founder and CEO of Transcriptic | https://www.forbes.com/profile/max-hodak/
- [Mastodon, Retrieved 2026] Emma Zhou background |
- [Matt Helfgott - Science | LinkedIn, Retrieved 2026] Company mission statement |
- [Science Corporation] Biohybrid architecture | https://science.xyz/technologies/biohybrid/
- [Science Corporation] SciFi headstage pricing | https://science.xyz/news/scifi-headstage/
- [The Next Web, Retrieved 2026] Trials for a brain sensor could begin in 2027 |
- [Antonia E. - Science | LinkedIn, Retrieved 2026] Company scaled to 150+ over 3 years |